Adipotide
A pro-apoptotic peptidomimetic targeting white adipose tissue vasculature — striking rodent obesity reversal data, no clinical development pathway.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
Originally developed at MD Anderson, adipotide is a peptidomimetic designed to selectively destroy the vasculature supplying white adipose tissue, producing dramatic obesity reversal in rodent and primate models. Clinical development has not advanced; the renal-toxicity profile is the principal obstacle.
- Class
- Pro-apoptotic peptidomimetic targeting white adipose tissue vasculature
- Sponsor
- Originally MD Anderson Cancer Center; no active pharmaceutical program
- Stage
- Preclinical
- Lead use case
- Severe obesity research
What it is
Adipotide (FTPP — Fat Targeted Pro-apoptotic Peptide) is a peptidomimetic compound designed by Renata Pasqualini and Wadih Arap's group at MD Anderson Cancer Center. It consists of two functional motifs: a homing sequence (CKGGRAKDC) that selectively binds prohibitin on white adipose tissue endothelial cells, and a pro-apoptotic sequence that triggers programmed cell death in the bound vasculature. The combination produces selective destruction of white adipose tissue blood supply with subsequent fat-tissue loss.
Current research status
Adipotide produced striking obesity-reversal data in rodent and rhesus monkey models in published 2004 and 2011 research. A small Phase 1 program was initiated in cancer-cachexia and obesity-related contexts but did not advance into broader clinical development. Renal toxicity in the rhesus studies is a principal obstacle, and the molecule is not in active pharmaceutical development today. It remains a frequently-cited preclinical milestone in obesity research and a recurring topic in advanced biohacker discussions.
Mechanistic rationale
The CKGGRAKDC homing sequence binds prohibitin selectively expressed on the endothelial cells of white adipose tissue vasculature. The conjugated D(KLAKLAK)2 pro-apoptotic motif disrupts mitochondrial membranes upon internalization, triggering apoptosis in the bound endothelial cells. Loss of vascular supply to white adipose tissue produces selective fat-tissue regression — fundamentally different from any approved obesity pharmacology, which acts on appetite or metabolism rather than on adipose tissue vasculature directly.
Available evidence
Original rodent obesity reversal (Kolonin et al., Nat Med 2004) — Daily adipotide administration produced dramatic and specific white adipose tissue loss in obese mice without significant effects on lean tissue.[1]
Rhesus monkey study (Barnhart et al., Sci Transl Med 2011) — Confirmed obesity reversal in obese rhesus monkeys with body weight reductions of approximately 11% over 4 weeks. Renal toxicity (tubular nephropathy) emerged as a dose-limiting consideration.[2]
Human Phase 1 development — Limited data; the program has not advanced.
Why it's interesting
Adipotide is mechanistically distinct from every approved or development-stage obesity therapeutic — it operates by destroying adipose tissue vasculature rather than by modifying appetite, energy expenditure, or nutrient absorption. The rodent and primate data is striking enough that the molecule recurs in obesity-research and biohacker discussions despite its dormant clinical status. For users following the obesity pharmacology field, adipotide is a useful reference point for what radically-different mechanisms can produce in animal models.
Limitations & risks
Renal toxicity in rhesus studies is the principal clinical-translation obstacle. The mechanism — inducing cell death in adipose vasculature — is fundamentally different in safety profile from the metabolic-modulation mechanisms of approved obesity therapy. Long-term effects of repeated cycles of adipose vascular destruction and remodeling are not characterized. The clinical development pathway is not active.
Community discussion notes
Adipotide is a topic of recurring interest in advanced biohacker and obesity-research circles because of the dramatic preclinical results. The discussions sometimes underweight the renal-toxicity findings and the absence of an active clinical development program; the appropriate reading is that adipotide is fascinating preclinical pharmacology, not a translatable therapy at the present time.
The takeaway
Adipotide is one of the more striking preclinical obesity-research molecules — radically different mechanism of action from all approved options, dramatic effects in rodent and primate models. The renal-toxicity findings and absence of an active clinical program place it firmly in the preclinical-curiosity tier rather than the translatable-therapy tier. For users encountering it in vendor channels, the mismatch between the marketing potential and the actual development status should be a key part of the read.
References
- Kolonin MG, et al. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004;10(6):625-632. https://pubmed.ncbi.nlm.nih.gov/15133506/
- Barnhart KF, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011;3(108):108ra112. https://pubmed.ncbi.nlm.nih.gov/22072636/
- Hossen MN, et al. Adipose-targeted prohibitin-binding peptide-conjugated nanoparticles. Sci Rep. 2018;8:8101. https://pubmed.ncbi.nlm.nih.gov/29802328/